Testing BT200 in type 2B von Willebrand disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new medicine called BT200 (rondaptivon pegol) to see if it can safely help people with type 2B von Willebrand disease who have low platelets and recent bleeding problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have type 2B von Willebrand disease with low platelet counts and recent bleeding (like frequent bruises)
- You can understand the study and agree to take part
- You do not have other serious health issues that could make the study unsafe or affect the results
- You have not taken other experimental drugs in the past 30 days (or longer depending on the drug)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This study tests a new medicine called HMB-002 for people with von Willebrand disease. It aims to see if the drug can help control bleeding without needing regular preventive treatments.
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This study tests whether SR604, a new injection given under the skin, can reduce bleeding episodes in people with von Willebrand disease (a condition where blood doesn't clot properly). The trial will measure how well it works, how safe it is, and how your body processes it.
This trial tests whether a special algorithm can reduce repeat bleeding from the gut or nose in people with inherited Von Willebrand disease. If you have had serious nosebleeds or digestive bleeding, this study may help find a better way to manage your condition.
Hear when a new Von Willebrand Disease (VWD), Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.